These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25629369)

  • 1. Intralesional therapy for advanced melanoma: promise and limitation.
    Agarwala SS
    Curr Opin Oncol; 2015 Mar; 27(2):151-6. PubMed ID: 25629369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
    Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
    Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralesional immunotherapy as a strategy to treat melanoma.
    Nouri N; Garbe C
    Expert Opin Biol Ther; 2016; 16(5):619-26. PubMed ID: 26898656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
    Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL
    J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
    Garnock-Jones KP
    BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
    Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
    Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
    Stopeck AT; Jones A; Hersh EM; Thompson JA; Finucane DM; Gutheil JC; Gonzalez R
    Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
    J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.
    Harrington KJ; Andtbacka RH; Collichio F; Downey G; Chen L; Szabo Z; Kaufman HL
    Onco Targets Ther; 2016; 9():7081-7093. PubMed ID: 27895500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
    Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
    Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma.
    Bedikian AY; Richards J; Kharkevitch D; Atkins MB; Whitman E; Gonzalez R
    Melanoma Res; 2010 Jun; 20(3):218-26. PubMed ID: 20354459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
    Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
    Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in Intralesional Therapy for Metastatic Melanoma.
    Sloot S; Rashid OM; Sarnaik AA; Zager JS
    Cancer Control; 2016 Jan; 23(1):12-20. PubMed ID: 27009452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma.
    Gonzalez R; Hutchins L; Nemunaitis J; Atkins M; Schwarzenberger PO
    Melanoma Res; 2006 Dec; 16(6):521-6. PubMed ID: 17119453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
    Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N
    Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma.
    Weide B; Derhovanessian E; Pflugfelder A; Eigentler TK; Radny P; Zelba H; Pföhler C; Pawelec G; Garbe C
    Cancer; 2010 Sep; 116(17):4139-46. PubMed ID: 20564107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
    Andtbacka RH; Ross M; Puzanov I; Milhem M; Collichio F; Delman KA; Amatruda T; Zager JS; Cranmer L; Hsueh E; Chen L; Shilkrut M; Kaufman HL
    Ann Surg Oncol; 2016 Dec; 23(13):4169-4177. PubMed ID: 27342831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
    Chesney J; Awasthi S; Curti B; Hutchins L; Linette G; Triozzi P; Tan MCB; Brown RE; Nemunaitis J; Whitman E; Windham C; Lutzky J; Downey GF; Batty N; Amatruda T
    Melanoma Res; 2018 Feb; 28(1):44-51. PubMed ID: 29176501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
    J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.